Crossmark

The Promise and Perils of Transcatheter Aortic Valve Replacement (TAVR) in Low Surgical Risk Patients with Severe Aortic Stenosis in the Current Era

Published Online: 2024-08-16

Published Print: 2024-11

Authors

Hassanin, Ahmed

Szerlip, Molly
License Information

Text and Data Mining valid from 2024-08-16

Version of Record valid from 2024-08-16
More Information

Article History

Accepted: 5 August 2024

First Online: 16 August 2024

Compliance with Ethical Standards

:

: Ahmed Hassanin has no disclosures to report. Molly Szerlip reports being on the steering committees of Abbott Vascular and Medtronic; received payment from Edwards Lifesciences, Shockwave, and Abbott Vascular; and is on the advisory board of Boston Scientific.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current